PRAN vs. GLTO, TCRT, FLGC, NRSN, KALA, BIVI, APM, HUGE, ADXN, and ORGS
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Galecto (GLTO), Alaunos Therapeutics (TCRT), Flora Growth (FLGC), NeuroSense Therapeutics (NRSN), KALA BIO (KALA), BioVie (BIVI), Aptorum Group (APM), FSD Pharma (HUGE), Addex Therapeutics (ADXN), and Orgenesis (ORGS). These companies are all part of the "medical" sector.
Alterity Therapeutics (NASDAQ:PRAN) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.
Alterity Therapeutics has higher revenue and earnings than Galecto. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
Alterity Therapeutics' return on equity of 0.00% beat Galecto's return on equity.
In the previous week, Galecto had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Galecto and 0 mentions for Alterity Therapeutics. Galecto's average media sentiment score of 1.33 beat Alterity Therapeutics' score of 0.00 indicating that Galecto is being referred to more favorably in the news media.
Alterity Therapeutics received 158 more outperform votes than Galecto when rated by MarketBeat users. However, 58.82% of users gave Galecto an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote.
3.6% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 12.1% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Alterity Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Galecto has a consensus price target of $5.33, suggesting a potential upside of 668.82%. Given Galecto's higher possible upside, analysts plainly believe Galecto is more favorable than Alterity Therapeutics.
Summary
Galecto beats Alterity Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Alterity Therapeutics Competitors List
Related Companies and Tools